10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

CDK7 Antibody

Rabbit mAb
Catalog # AP90821

Product Information

Application	WB
Primary Accession	P50613
Reactivity	Human
Clonality	Monoclonal
Other Names	Cyclin-dependent kinase 7; p39 Mo15; CDK-activating kinase 1; Cell division protein kinase 7; CDK7; CAK; CAK1; CDKN7; MO15; STK1;
Isotype	Rabbit IgG
Host	Rabbit
Calculated MW	39038

Additional Information

Dilution	WB 1:1000~1:2000
Purification	Affinity-chromatography
Immunogen	A synthesized peptide derived from human CDK7
Description	CDK-activating kinase (CAK) is a complex of CDK7 and cyclin H. The complex is involved in cell cycle regulation by phosphorylating an activating residue in the T-loop domain of cdks. Regulation of CAK activity is mediated by T-loop phosphorylation and by association with MAT1, both of which enhance its kinase activity toward the CTD of RNA polymerase II and other substrates such as p53.
Storage Condition and Buffer	Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at +4°C short term. Store at -20°C long term. Avoid freeze / thaw cycle.

Protein Information

Name	CDK7
Synonyms	CAK, CAK1, CDKN7, MO15, STK1
Function	Serine/threonine kinase involved in cell cycle control and in RNA polymerase II-mediated RNA transcription (PubMed:9852112, PubMed:19136461, PubMed:26257281, PubMed:28768201). As a cyclin- dependent kinase, CDK7 is activated by the binding to cyclin-H/CCNH and the CDK-activating kinase assembly factor MAT1 (PubMed:41100585). Catalytic subunit of the CDK-activating kinase (CAK) complex, a master regulator of CDK activity by catalyzing the activating threonine phosphorylation of CDKs (PubMed:41100585). CAK activates major mediators of cell cycle control, including CDK1, CDK2, CDK4 and CDK6, and plays a key role in regulating cell cycle progression (PubMed:41100585). CAK complexed to the core-TFIIH basal

transcription factor activates RNA polymerase II by serine phosphorylation of the CTD of POLR2A, allowing its escape from the promoter and elongation of the transcripts (PubMed:9852112). Initiates transcription by RNA polymerase II by mediating phosphorylation of POLR2A at 'Ser-5' of the repetitive C-terminal domain (CTD) when POLR2A is in complex with DNA, promoting dissociation from DNA and initiation (PubMed:19136461, PubMed:26257281, PubMed:28768201). Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11 (PubMed:9372954, PubMed:9840937, PubMed:19136461, PubMed:26257281, PubMed:28768201, PubMed:41100585, PubMed:41100585). Its expression and activity are constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 activation by phosphorylation, but is inactivated in turn by p53/TP53; this feedback loop may lead to an arrest of the cell cycle and of the transcription, helping in cell recovery, or to apoptosis. Required for DNA-bound peptides-mediated transcription and cellular growth inhibition.


Cellular Location

Nucleus. Cytoplasm. Cytoplasm, perinuclear region. Note=Colocalizes with PRKCI in the cytoplasm and nucleus (PubMed:15695176). Translocates from the nucleus to cytoplasm and perinuclear region in response to DNA-bound peptides (PubMed:19071173).

Tissue Location

Ubiquitous.

Images



Western blot analysis of CDK7 expression in MCF-7 cell lysate.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.